Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-28 | Adam Koppel, M.D., Ph.D. Nominating and Corporate Governance Committee Age 44 Dr. Koppel has served as a member of our Board since March 2013. Since November 2003, Dr. Koppel has served as a Managing Director of Brookside Capital, LLC, the public equity affiliate of Bain Capital. Prior to joining Brookside Capital, LLC, he was an Associate Principal with McKinsey & Company where he consulted to companies in the pharmaceutical and biotechnology industries. Dr. Koppel received an M.D. and Ph.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. from Harvard University. We believe that Dr. Koppel is qualified to serve on our Board due to his extensive experience as an investment banking and financial professional and his extensive personal knowledge of the pharmaceutical and biotechnology industries. |
| 2015-04-28 | Adam Koppel, M.D., Ph.D. Nominating and Corporate Governance Committee Age 45 Dr. Koppel has served as a member of our Board since March 2013. Since May 2014, Dr. Koppel has served as Senior Vice President and Chief Strategy Officer of Biogen Idec Inc., a biotechnology company. ... We believe that Dr. Koppel is qualified to serve on our Board due to his extensive experience as an investment banking and financial professional and his extensive knowledge of the pharmaceutical and biotechnology industries. 2014 Director Compensation Table shows Adam Koppel, M.D., Ph.D. received total compensation of $230,412. |
| 2017-04-28 | Dr. Koppel has served as a member of our Board since March 2013. He currently serves on the Audit Committee and the Nominating and Corporate Governance Committee. |
Data sourced from SEC filings. Last updated: 2026-03-14